Monday, June 27, 2022
  SocialTwist Tell-a-Friend  

MUMBAI, India, May 9, 2022 /PRNewswire/ --  Datar Cancer Genetics ("Datar"), a world-leading cancer research corporation today announced a $250 million contract with Artemis DNA, a leading USA-based diagnostic laboratory company that provides proprietary Next Generation Sequencing (NGS) genetic testing and diagnostic laboratory services for a wide variety of medical specialties, including cardiology, oncology, immunology, neurology, reproductive health and pharmacogenomics. Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.


The deal covers two solutions from Datar's cancer screening and diagnostic portfolio  - Trucheckâ„¢  Pragma  and Cancertrackâ„¢.  Trucheckâ„¢ Pragma is a non-invasive, blood-based screening test for Lung, Stomach, Colon, Pancreas, Prostate, Breast, and  Ovarian cancers. Cancertrackâ„¢  is for the evaluation of response/resistance/recurrence during the management of cancer. The solutions  will be presently offered as Laboratory Developed Tests (LDTs) in the USA.

In addition, Artemis DNA will provide Datar with high-complexity CLIA certified, CAP-accredited testing facilities in Texas and California to enable the commercial launch of various cancer screening and diagnostic tests developed by Datar.

"We are extremely delighted to offer our highly accurate cancer detection technology for the benefit of patients in the USA  and Vietnam in partnership with Artemis DNA. Their marketing strength and experience will enable a seamless roll-out of our innovative, game-changing, life-saving Liquid Biopsies," commented Mr. Rajan Datar, Chairman of Datar Cancer Genetics. "We will continue to expand our offerings in the USA and European markets with high standards of accuracy and quality of service," he added.

"We are so excited to be able to offer the ground-breaking technologies to patients in the USA and Vietnam," commented Ms. Emylee Thai, Founder and CEO of Artemis DNA. "Datar Cancer Genetics continues to innovate and push the boundaries on what people thought was impossible when it comes to cancer screening, diagnosis and management. Artemis DNA is proud to be part of the pioneers to help change the landscape of early screening and diagnosis, as well as management of cancer, which will improve and save lives."

Datar Cancer Genetics is a global oncology research and applications company specializing in non-invasive technologies for improved detection, treatment, and management of cancer. Datar's state-of-the-art facility is ISO, CAP-accredited and CLIA certified. Datar's tests for early detection of Breast and Prostate cancer have been granted 'Breakthrough Designation' by the US FDA. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India. The Company has already established an advanced research and testing facility at Guildford, UK, and is pursuing large clinical studies across various geographies  to cover multiple cancers where there is a potential for cure with early detection. The Company also proposes to roll out multiple test centers globally.

CONTACT: Dr. Vineet Datta




More News by PR Newswire India

IAS Announces Campaign Sync Solution with Xandr's Invest DSP to Match Advertisers' Pre- and Post-bid Settings

Shahani Group Chairperson Mrs Maya Shahani Featured in The Knowledge Review's 2022 Listing of India's Most Admired Women in the Education Sector

Court Lifts Final Injunction in Favor of Altair in World Programming Case

Medvarsity partners with McGraw Hill to augment its courses and improve learning outcomes

PHD Media and 1862 OML win big at the Inkspell Media's MarTech Fest held on 24th June in New Delhi

Sigmoid strengthens financial services, industrial, and media offerings with accelerators and hiring deep domain experts

Thailand Draws on Creativity, Technology to Answer Consumer Demand for Eco-Friendly Lifestyle Goods

JOYSBIO offers SARS-COV-2 Antigen Rapid Test that detects Omicron subvariants BA.4 and BA.5

Global Secure SD-WAN Solutions Thrive as Organizations Turn to Cloud and 5G

Top 3 Countries for Future Growth Potential: The United States, Norway, and the United Kingdom

Abcam: Appointment of Vice President of Investor Relations

LIXIL announces winners and continuing support of the Asia Pacific Property Awards 2022-23

The 7th edition of the Embedded Safety & Security Summit culminated with a triumph

Myntra StyleCast rolls out Campus Ambassador Program, kick starting the journey for ~500 aspiring young creators from leading colleges

CSM Tech wins IMC Awards for transformation at JSW mines

12th DBN Science and Technology Award Ceremony to Further Broaden the Vision of Agricultural Innovation

Petal Search wins iF Award 2022, signaling its dedication to next-generation search engine

Hisense Praises Women Football Players through #RememberTheName Campaign, Commits to Enhancing Tournament Experience

CGTN: Why China's development philosophy can help promote global prosperity

Theme song "We Will Be Better" echoes 25th anniversary of HK's return to motherland

Amit Shah chairs Parliamentary Consultat...
Jharkhand Health Minister boycotts Centr...
SC to hear on Monday pleas by Shinde, re...
Jharkhand Bypolls: Cong's Shilpi Neha Ti...
Drugs worth about Rs 15 cr seized in Ass...
Apple offers students with discounts on ...
 Top Stories
Trailer of Gujarati film 'Vickida N... 
Pakistan irked over BRICS meeting s... 
G7 nations unite to address evolvin... 
Dharm Guru offers puja in Indore ci... 
Formula 1 pushing towards net zero ... 
China-Japan tensions flare up over ... 
Dr Thejo Kumari Amudala bags Taj Mr... 
Iran says "indirect" sanctions talk...